Skip to main content

Table 1 Sample characteristics (n = 343)

From: Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time

CharacteristicsMean ± SD / n (%)
Age (years)55.15 ± 9.36
Race
 Chinese269 (78.4)
 Non-Chinese Asians31 (9.0)
 Caucasian43 (12.5)
Gender
 Female256 (74.6)
 Male87 (25.4)
Cancer diagnosis
 Gynecological (ovary, cervix, endometrium, genital tract)45 (13.1)
 Lung48 (14.0)
 Head and neck30 (8.7)
 Breast174 (50.7)
 Urinary tract (prostate, bladder, uterus)17 (5.0)
 Gastrointestinal (esophagus, pancreas, stomach, bile duct, colon-rectum)29 (8.5)
Cancer stage
 Stage I52 (15.2)
 Stage II99 (28.9)
 Stage III116 (33.8)
 Stage IV76 (22.2)
Treatment intent
 Radical (adjuvant)199 (58.0)
 Radical (neoadjuvant)51 (14.9)
 Radical (concurrent)30 (8.7)
 Palliative63 (18.4)
Chemotherapy agents
 Docetaxel122 (35.6)
 Paclitaxel33 (9.6)
 Cisplatin42 (12.2)
 Carboplatin8 (2.3)
 Oxaliplatin9 (2.6)
 Carboplatin + Paclitaxel50 (14.6)
 Carboplatin + Docetaxel29 (8.5)
 Vinorelbine31 (9.0)
 Xelox19 (5.5)
Diabetes History
 Yes54 (15.7)
  1. Abbreviation: SD standard deviation